Revenio Group
REG1V.HE Small CapHealthcare · Medical Devices
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare
Revenio Group Stock at a Glance
Revenio Group (REG1V.HE) is currently trading at €12.50 with a market capitalization of $363.6M. The trailing P/E ratio stands at 21.19x, with a forward P/E of 12.87x. The 52-week range spans from €12.02 to €29.10; the current price is 57% below the yearly high. Year-over-year revenue growth stands at +4.6%. The net profit margin stands at 14.15%.
💰 Dividend
Revenio Group pays an annual dividend of €0.40 per share, representing a yield of 3.2%. The payout ratio stands at 67.85%.
📊 Analyst Rating
4 analysts rate Revenio Group (REG1V.HE) on consensus: None. The average price target is €19.38, implying +55% from the current price. Analyst price targets range from €15.00 to €23.50.
Revenio Group: The Investment Case in Detail
Revenio Group (REG1V.HE) operates in the Healthcare — specifically Medical Devices — and is headquartered in Finland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
With a gross margin near 69.94%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
The Bear Case
Revenue growth has slowed to just 4.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy.
Valuation in Context
At a PEG of 6.37, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.
What to Watch Next
- The forward P/E of 12.87x is meaningfully below the trailing 21.19x — analysts expect earnings to step up; the next earnings release is the test.
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The dividend yield near 3.2% combined with a payout ratio of 67.85% leaves room for further hikes — a track record of consecutive raises is a strong income signal.
- The analyst consensus price target implies 55% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 69.94% — indicates pricing power
- Solid dividend yield of 3.2%
- Solid balance sheet with low debt (D/E 9.21)
- Positive free cash flow
No significant red flags in current metrics.
Technical Snapshot
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Risk Profile
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
Revenio Group: the quiet Finnish glaucoma champion riding an aging-eyes megatrend
The Real Story
Revenio Group makes one product family really well: handheld and portable tonometers under the iCare brand — devices that measure intraocular eye pressure to diagnose glaucoma without anesthesia. Sounds niche; in fact, glaucoma is the leading cause of irreversible blindness worldwide, and the patient pool grows roughly 4 percent a year as the global population ages.
Where Revenio is special is the home-monitoring extension. Traditional intraocular-pressure measurement requires a clinic visit on a Goldmann tonometer — uncomfortable, infrequent, anesthesia. The iCare HOME2 lets the patient measure at home several times a day, generating a pressure-curve the ophthalmologist actually finds useful for medication titration. That is a workflow change, not just a product, and it explains the gross margins above 60 percent.
What Smart Money Thinks
Finnish institutional ownership is heavy: domestic pension funds and insurance companies hold roughly 35 percent. Free-float concentrated in Helsinki retail. No public US 13F whale. Insider ownership ~7 percent including founder-family roots.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
📉 The 3 Real Bear Points
Valuation in Context
At 13.96 euros with 0.59 euros trailing EPS the P/E of 23.7 is typical for a quality med-tech with a real moat. Forward P/E 14.4 prices in mid-teens earnings growth. EV/EBITDA 15.4 is in the upper half for European small-cap med-tech but not extreme. Fair-priced rather than cheap.
🗓️ Next 3 Catalyst Dates
- :
- :
- :
💬 Daniel's Take
Revenio is the kind of small-cap European med-tech I like to own quietly for 5 to 10 years. The product is essential, the demographics tail is structural, the dividend gets paid, management runs the company conservatively from Vantaa, Finland. P/E 23.7 is not a gift, but for compounding mid-teens growth at high margins it is fair. I would size 1 to 2 percent and add on dips below 12 euros. Risk is a clinical-trial setback on next-gen products; reward is steady compounding plus possible M&A premium.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Revenio Group?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news